SANXING(SH:601567) Sou Hu Cai Jing·2025-04-27 20:30Group 1 - The core viewpoint of the news is that Samsung Medical has shown strong financial performance in 2024, with significant growth in revenue and net profit [2][3] Group 2 - As of April 25, 2025, Samsung Medical's stock closed at 26.22 yuan, down 0.64%, with a turnover rate of 1.17% and a trading volume of 164,000 shares, amounting to a transaction value of 436 million yuan [1] - On April 25, 2025, the capital flow for Samsung Medical indicated a net inflow of 7.95 million yuan from institutional investors and 17.06 million yuan from retail investors, while retail investors had a net outflow of 25.02 million yuan [1][3] - As of March 31, 2025, the number of shareholders for Samsung Medical decreased to 16,400, a reduction of 898 shareholders or 5.2%, while the average shareholding increased to 86,200 shares [1][3] Group 3 - Samsung Medical's 2024 annual report highlights a total revenue of 14.6 billion yuan, representing a year-on-year increase of 27.38%, and a net profit attributable to shareholders of 2.26 billion yuan, up 18.69% year-on-year [2][3] - The company's net profit after deducting non-recurring items reached 2.20 billion yuan, reflecting a year-on-year growth of 31.92% [2] - In Q4 2024, Samsung Medical reported a quarterly revenue of 4.167 billion yuan, a year-on-year increase of 33.35%, and a quarterly net profit of 444 million yuan, up 7.11% year-on-year [2]